Trials / Completed
CompletedNCT06655545
18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
A Single-center, Real-world Study Exploring the Guidance of FES-PET for First-line Treatment of HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 473 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A single-center, real world study to evaluate the role of FES-PET in guiding the first-line treatment of HR+/HER2- MBC patients.
Conditions
Timeline
- Start date
- 2023-07-15
- Primary completion
- 2024-10-15
- Completion
- 2025-02-01
- First posted
- 2024-10-23
- Last updated
- 2025-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06655545. Inclusion in this directory is not an endorsement.